Ascent Case Series: Knee Osteoarthritis

PATIENT HISTORY

An active 71-year-old female presented with a history of rheumatoid arthritis and bilateral knee osteoarthritis (OA). Her left knee was constantly swollen and a review of X-rays revealed OA characterized as Kellgren-Lawrence Grade 4. She was first diagnosed with OA 5-6 years earlier and received an intra-articular cortisone injection that provided limited relief. Seven months prior to her Ascent injection, she received a hyaluronic acid injection that provided only a mild improvement in pain.

INTERVENTION

Ascent™ is an injectable amniotic fluid allograft designed to protect, cushion, lubricate, and reduce inflammation in fluid environments, such as joints and tendons. Ascent is processed using the patent-pending Selectify™ process that selects key amniotic fluid components and preserves the allograft in a shelf-stable format. The physician administered a 15 mg dose of Ascent reconstituted with 1 cc of 0.9% sterile saline. 40 cc of synovial fluid were aspirated and lidocaine was used as a numbing agent. No immediate adverse reactions or complications occurred.

RESULTS

The patient was asked to complete a Visual Analog Scale (VAS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) immediately prior to injection (baseline), at 1 month, 2 months, and 3 months after the Ascent injection. The patient saw immediate and sustained improvements in both VAS and KOOS over her baseline responses. VAS improved from a baseline of six to two at 1 month, two at 2 months, and one at 3 months after her Ascent injection. KOOS reporting showed improvements over baseline for every reported metric including pain, symptoms, average daily living, and quality of life.



For more information, visit stimlabs.com

© 2017 StimLabs LLC. ASCENT and SELECTIFY are trademarks of StimLabs LLC. LBL17-014 Rev 01